Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Crucell Vaccine Stops AIDS in Monkeys
Volgen
www.bloomberg.com/apps/news?pid=20601... Crucell Vaccine Stops AIDS in Monkeys, Harvard Scientist Says By Simeon Bennett Nov. 9 (Bloomberg) -- Crucell NV's experimental AIDS vaccine kept six monkeys from getting an animal equivalent of the disease, suggesting a decades-long search for ways to stop the deadly infection isn't yet at a dead end. Researchers from Leiden, Netherlands-based Crucell and Beth Israel Deaconess Medical Center in Boston reduced levels of simian immunodeficiency virus, or SIV, in the monkeys as much as 250-fold and held off AIDS for more than 500 days, according to a report in the online edition of the journal Nature. They're now testing a similar form of the vaccine in 48 healthy people. Last year, a vaccine being developed by New York-based Merck & Co., which had also appeared to benefit monkeys, failed in human testing. The problems appeared linked to a cold virus in the vaccine, which unexpectedly raised people's risk of getting AIDS. While the initial Crucell-Harvard vaccine recipe won't be used in humans because it contains the same cold virus, it does offer some promise, said Dan Barouch, the lead author and a virologist at Harvard University and Beth Israel. ``Our new data suggests we're not at the end of the road when it comes to vaccine development,'' he said in a Nov. 7 telephone interview. Crucell is a biotechnology company that markets vaccines and antibodies to treat infectious diseases such as influenza, hepatitis A and B, and typhoid fever. The company's best-selling product is Quinvaxem, a liquid vaccine co-developed with Basel, Switzerland-based Novartis AG and launched in 2006 that protects against five childhood diseases. Last month, Crucell month won a $30-million U.S. contract to develop vaccine to fight the Ebola and Marburg viruses. HIV, the human immunodeficiency virus that causes AIDS, infects 2.7 million people each year, mostly in Africa. Strong Immune Response Barouch achieved the result by giving the monkeys two disabled cold-causing viruses six months apart. Each of these ``ferry'' viruses contained a hidden cargo: a single SIV protein that prompted the animals to produce masses of so-called ``killer T-cells'' that are primed to hunt and destroy SIV- infected cells. A year after the first shots, the researchers gave the monkeys a lethal dose of SIV, and found their T-cells reduced SIV viral levels as much as 250-fold, stopping its spread and preventing the animals from progressing to simian-AIDS. Four of six monkeys who received placebo shots were dead by about 350 days. ``It certainly is better than the previous animal models, but we still don't know -- and it's a big if - whether this is going to translate into a meaningful and useful human model,'' Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, said in a Nov. 7 telephone interview. Rare Virus Used The vaccine may have worked because the researchers used a rare virus as the ferry for the first shot called adenovirus-26, to which humans don't typically have natural immunity. The ferry virus used for the second ``booster'' shot was the more common adenovirus-5, the same one used in the failed Merck trial, against which many people are immune. Unlike Merck's monkey studies, Barouch and colleagues used only animals lacking a genetic mutation that predisposes them to fight SIV. That makes his results the ``most robust'' in years for adenovirus-based animal trials, Fauci said. ``He stacked the cards against himself,'' he said. ``It's another step in the direction hopefully that will get us to a T- cell based vaccine that would be of some use clinically.'' Barouch's team is now testing the adenovirus-26-based shot in a patient study at Brigham and Women's Hospital in Boston. They haven't yet decided which virus to use for the second shot, though it won't be adenovirus-5, and may be Ad26, Barouch said. Both the monkey study and the ongoing human trial are funded by grants from the U.S. National Institutes of Health. To contact the reporter on this story: Simeon Bennett in Singapore at sbennett9@bloomberg.net Last Updated: November 9, 2008 13:00 ES (van het HIV draadje)
www.nature.com/nature/journal/vaop/nc... Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys Jinyan Liu1, Kara L. O'Brien1, Diana M. Lynch1, Nathaniel L. Simmons1, Annalena La Porte1, Ambryice M. Riggs1, Peter Abbink1, Rory T. Coffey1, Lauren E. Grandpre1, Michael S. Seaman1, Gary Landucci2, Donald N. Forthal2, David C. Montefiori3, Angela Carville4, Keith G. Mansfield4, Menzo J. Havenga5, Maria G. Pau6, Jaap Goudsmit6 & Dan H. Barouch1 1. Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA 2. University of California, Irvine School of Medicine, Irvine, California 92697, USA 3. Duke University Medical Center, Durham, North Carolina 27710, USA 4. New England Primate Research Center, Southborough, Massachusetts 01772, USA 5. TNO Biosciences, 2301 CE, Leiden, The Netherlands 6. Crucell Holland BV, 2301 CA, Leiden, The Netherlands A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans1, 2. Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing simian immunodeficiency virus (SIV) Gag failed to reduce peak or setpoint viral loads after SIV challenge of rhesus monkeys (Macaca mulatta) that lacked the protective MHC class I allele Mamu-A*01 (ref. 3). Here we show that an improved T-cell-based vaccine regimen using two serologically distinct adenovirus vectors afforded substantially improved protective efficacy in this challenge model. In particular, a heterologous rAd26 prime/rAd5 boost vaccine regimen expressing SIV Gag elicited cellular immune responses with augmented magnitude, breadth and polyfunctionality as compared with the homologous rAd5 regimen. After SIVMAC251 challenge, monkeys vaccinated with the rAd26/rAd5 regimen showed a 1.4 log reduction of peak and a 2.4 log reduction of setpoint viral loads as well as decreased AIDS-related mortality as compared with control animals. These data demonstrate that durable partial immune control of a pathogenic SIV challenge for more than 500 days can be achieved by a T-cell-based vaccine in Mamu-A*01-negative rhesus monkeys in the absence of a homologous Env antigen. These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1.
Super bericht, veel toegevoegde waarde voor Crucell. Eigenlijk wel logisch om met een voor mensen redelijk onbekend virus te werken als transport middel. Zolang dit virus onbekend blijft heeft het grote kans op slagen denk ik.
"In the face of our engineered assassin cells, the virus will either die or be forced to change its disguises again, weakening itself along the way," added Andy Sewell of Britain's Cardiff University. Perhaps having to mutate will weaken the virus, the researchers said. They plan to test the T-cell treatment in HIV patients next year. "We have managed to engineer a receptor that is able to detect HIV's key fingerprints and is able to clear HIV infection in the laboratory," said Bent Jakobsen, chief scientific officer at Adaptimmune Ltd, a British company launched in July that owns the rights to the technology. "If we can translate those results in the clinic, we could at last have a very powerful therapy on our hands." (Reporting by Maggie Fox; Editing by Cynthia Osterman)
www.reuters.com/article/marketsNews/i... Souped-up immune cells catch even disguised HIV WASHINGTON, Nov 9 (Reuters) - Genetically engineered immune cells can spot the AIDS virus even when it tries to disguise itself, offering a potential new way to treat the incurable infection, researchers reported on Sunday. The killer T-cells, dubbed "assassin" cells, were able to recognize other cells infected by HIV and slow the spread of the virus in lab dishes. If the approach works in people, it might provide a new route of treating infection with the deadly human imunnodeficiency virus, the researchers in the United States and Britain said. "Billions of these anti-HIV warriors can be generated in two weeks," said Angel Varela-Rohena of the University of Pennsylvania, who helped lead the study. In a second, unrelated report, researchers testing Dutch biotechnology firm Crucell NV's (CRCL.AS: Quote, Profile, Research, Stock Buzz) (CRXL.O: Quote, Profile, Research, Stock Buzz) experimental AIDS vaccine said it prevented infection in six monkeys. The animals were infected with a monkey version of HIV called SIV, and the vaccine used a virus that is dangerous to use in humans, so it is not ready for human tests. But, writing in the journal Nature, Dr. Dan Barouch of Beth Israel Deaconess Medical Center and Harvard Medical School in Boston and colleagues said it shows there is still hope for developing a vaccine against AIDS. The AIDS virus, which infects 33 million people globally, is especially hard to fight. Like all viruses, it hijacks cells in its victims, forcing them to become little viral factories and make more virus. ESCAPE AND EVADE HIV is even more insidious, attacking immune system cells called CD4 T cells, which help mount a defense. It can also disguise itself to escape CD8 killer cells, also known as cytotoxic T lymphocytes or CTLs. "CTLs are crucial for the control of HIV infection. Unfortunately, HIV has an arsenal of mutational and nonmutational strategies that aid it in escaping from the CTL response mounted against it by its host," the researchers wrote in their report, published in the journal Nature Medicine. One good defense allows HIV to hide a protein called HLA-I-associated antigen. Varela-Rohena and colleagues took T-cells from an HIV patient and created a genetically engineered version that recognizes this deception. "It is possible to improve on nature when it comes to preventing HIV CTL escape," they wrote. Not only could the engineered T-cells see HIV strains that had escaped detection by natural T-cells, "but the engineered T cells responded in a much more vigorous fashion so that far fewer T-cells were required to control infection," Penn's James Riley, who also worked on the study, said in a statement. Continued...
Tests on cell therapy to fight HIV James Randerson, science correspondent guardian.co.uk, Monday November 10 2008 00.01 GMT The Guardian, Monday November 10 2008 Article history Researchers have developed a new "assassin cell" therapy for treating HIV which involves engineering the patient's own immune system to fight the virus more effectively. The therapy - which has proved effective in laboratory tests using human cell cultures - will be tested in a clinical trial of 35 patients with advanced HIV infection that is due to start next summer. Efforts to find a traditional vaccine against HIV - the virus that causes Aids - have so far drawn a blank. "HIV mutates so quickly," said Dr Bent Jakobsen at Adaptimmune, the company in Oxford that is developing the new approach. "Gradually it gets better and better at escaping the detection of the immune system." Jakobsen and his colleagues began to pursue a different approach after investigating a patient who had resisted his HIV infection particularly effectively. "When we tested the T cells from this patient, it looked as if he was responding to a number of those variants that normally escape the immune system," he said. T cells are components of the immune system that attack and destroy cells within the body that are infected. In this patient, the T cell receptor protein seemed particularly good at recognising HIV antigens. The team isolated the receptor protein and then improved its ability to recognise HIV further by randomly mutating it. Treating patients will involve taking a blood sample and adding an engineered virus containing genes for the improved T cell receptor. The patient's own T cells then take up the genes and so are equipped with the improved receptor. These cells are then injected back into the patient. The clinical trial of 35 patients next summer will take place at the University of Pennsylvania in Philadelphia.
Breng dit bericht op de voorpagina aub. => aanbevelen.
Ik heb het bericht naar het anp gestuurd.nieuwsdienst@anp.nl Is iedereen echt zo sloom, dit is echt big nieuws. Veel beter dan een nieuwe licentie hier of daar.
eddy59 schreef:
Ik heb het bericht naar het anp gestuurd.
nieuwsdienst@anp.nl Is iedereen echt zo sloom, dit is echt big nieuws.
Veel beter dan een nieuwe licentie hier of daar.
Eddy er wordt weinig aandacht besteedt aan dit bericht als ik de koers zie van 10,59 en slechts een volume van 80.931 Begrijp ik het goed dat het volgend jaar al op mensen wordt getest. Het zit toch pas in de beginfase van het onderzoek. Of lees ik het verkeerd Groetjes, Sappas
sappas schreef:
Begrijp ik het goed dat het volgend jaar al op mensen wordt getest. Het zit toch pas in de beginfase van het onderzoek.
"Barouch's team is now testing the adenovirus-26-based shot in a patient study at Brigham and Women's Hospital in Boston. They haven't yet decided which virus to use for the second shot, though it won't be adenovirus-5, and may be Ad26, Barouch said." Zie ook betreffende PB van Crucell (3 april 08)investors.crucell.com/C/132631/PR/200... "The phase I clinical study will be conducted at the Brigham and Women's Hospital (BWH) in Boston and will focus on assessing the safety and immunogenicity of the vaccine. The study will involve 48 healthy volunteers."
sappas schreef:
[quote=eddy59]
Ik heb het bericht naar het anp gestuurd.
nieuwsdienst@anp.nl Is iedereen echt zo sloom, dit is echt big nieuws.
Veel beter dan een nieuwe licentie hier of daar.
Eddy er wordt weinig aandacht besteedt aan dit bericht als ik de koers zie van 10,59 en slechts een volume van 80.931 Begrijp ik het goed dat het volgend jaar al op mensen wordt getest. Het zit toch pas in de beginfase van het onderzoek. Of lees ik het verkeerd Groetjes, Sappas Inderdaad het wordt volgend jaar op mensen getest. Vorige keer werkte het niet omdat de transporteur een bekend koude virus was waar tegen veel mensen al immune zijn. Nu gebruiken ze een vrij onbekend virus waartegen het menselijk lichaam nog geen immune stoffen heeft aangemaakt. Dit virus krijgt nu een code mee die het AIDS virus opspoort en vernietigd. Eddy
Waarom zou men persé met het Ad5 verder willen gaan (Ad5 = the most commonly used recombinant vaccine vector, adenovirus serotype 5), in deze studie mogelijk bij de herhaling van de (boost) vacinnatie. Wat is de onderliggende reden ? Wie en wat heeft er belang bij als zoveel mensen er reeds immuun voor zijn ?
[quote=aossa] Waarom zou men persé met het Ad5 verder willen gaan (Ad5 = the most commonly used recombinant vaccine vector, adenovirus serotype 5), in deze studie mogelijk bij de herhaling van de (boost) vacinnatie. Wat is de onderliggende reden ? Wie en wat heeft er belang bij als zoveel mensen er reeds immuun voor zijn ? Wat ik lees is dat het wel werkt zolang de dragen van de anti bodies maar onbekend is voor het menselijk lichaam zodat er een afweer reactie wordt veroorzaakt.
eddy59 schreef:
[quote=aossa]
Waarom zou men persé met het Ad5 verder willen gaan (Ad5 = the most commonly used recombinant vaccine vector, adenovirus serotype 5), in deze studie mogelijk bij de herhaling van de (boost) vacinnatie.
Wat is de onderliggende reden ?
Wie en wat heeft er belang bij als zoveel mensen er reeds immuun voor zijn ?[/quote]
Wat ik lees is dat het wel werkt zolang de dragen van de anti bodies maar onbekend is voor het menselijk lichaam zodat er een afweer reactie wordt veroorzaakt.
Het Ad5 zou bij vele mensen dus niet werken wegens de vooraf opgebouwde immuniteit. Vandaar mijn vraag ... 'wie en wat heeft daar belang bij' ? BTW @eddy59 Waarom 'quote' jij steeds in het kader ? Antwoorden NA de laatste '/quote' aub. Zoals je wel merkt lukt het MIJ wel !
eddy59 schreef:
[quote=aossa]
Waarom zou men persé met het Ad5 verder willen gaan (Ad5 = the most commonly used recombinant vaccine vector, adenovirus serotype 5), in deze studie mogelijk bij de herhaling van de (boost) vacinnatie.
Wat is de onderliggende reden ?
Wie en wat heeft er belang bij als zoveel mensen er reeds immuun voor zijn ?
Wat ik lees is dat het wel werkt zolang de dragen van de anti bodies maar onbekend is voor het menselijk lichaam zodat er een afweer reactie wordt veroorzaakt.
[/quote]
eddy: even leren quoten aub. Ik heb geen idee wie wat typt. Ga na het Quoten helemaal naar beneden in het bericht en begin pas te typen na de laatste " {/quote}". Veel succes.
Ik "begrijp" dat het ad5 juist niet gebruikt zal worden maar ad26.
[quote=aossa] [quote=eddy59] [quote=aossa] Het zou dus mogelijk kunnen zijn dat ze na verloop van tijd weer een ander onbekend(griep) virusje kunnen gebruiken als transporteur voor de kuur. Het lijkt mij wel lastig om het medicijn zodanig nieuw te houden dat het voor iedere patient nieuw is en dus antistoffen gaat aanmaken. Het klinkt in ieder geval fantastisch. Sorry weer fout gegaan, ik ga mij beteren.
eddy59 schreef:
Inderdaad het wordt volgend jaar op mensen getest.
@Eddy59: Fase I is al gestart, zie eerdere posting, en clinicaltrials.gov/ct2/show/NCT00618605 Jos
Inderdaad is het ons allemaal al wel bekend. PB Crucell April08 Start clinische test Juni08 De huidige berichten (via Bloomberg etc.) zijn naar aanleiding van publicatie in 'Nature' van gisteren zondag, 9 november.
Kopers en verkopers laten zich vandaag nauwelijks zien. Ik denk dat iedereen zijn adem inhoudt voor de cijfers morgen en weinig geboeid is door dit toch wat oude nieuws. Eerlijk gezegd vind ik de rust voor de cijfers wel prettig. De verwachtingen zijn misschien niet té hoog gespannen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
887,44
+0,99%
EUR/USD
1,0762
0,00%
FTSE 100
8.213,49
+0,51%
Germany40^
18.017,10
+0,67%
Gold spot
2.301,75
0,00%
NY-Nasdaq Composite
16.156,33
+1,99%
Stijgers
Dalers